RecruitingNCT07403188
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Sponsor
Kyverna Therapeutics
Enrollment
70 participants
Start Date
Nov 24, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Provided informed consent for the LTFU study
- Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol
Exclusion Criteria1
- Not applicable
Interventions
DRUGKYV-101
Autologous fully-human anti-CD19 chimeric antigen receptor T-cell (CD19 CAR T) product.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07403188
Related Trials
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT048734921 location
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment
NCT067824641 location
Plant-Based Diet for Patients With Rheumatoid Arthritis
NCT072683262 locations
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT074776392 locations